Chicago Atlantic Real Estate Finance, Inc. (REFI) Earnings Call Transcript & Summary
March 9, 2023
Earnings Call Speaker Segments
Tripp Sullivan
executiveThanks. Morning, everyone. Glad you could join us for the Chicago Atlantic Real Estate Finance Conference Call, where we'll go over what the company achieved in Q4 of 2022. Joining us on this call are John Mazarakis, our Executive Chairman; Tony Cappell, Chief Executive Officer; Andreas Bodmeier, Co-President and Chief Investment Officer; and Phil Silverman, Interim Chief Financial Officer. We put out our results earlier today through our earnings press release, which is available in the investor relations portion of our site, as is our supplemental that was filed with the SEC. A live audio webcast is accessible today as well; anyone who tunes into the replay should note that what we say here reflects the situation as of today, March 9, 2023, and nothing will be revised after this call. Some of the remarks and statements made during this call might qualify as forward-looking statements under the meaning set forth by securities laws, covering things like how our portfolio will perform going forward, our pipeline of possible loans and other investments, upcoming dividends, and financing activity. Every forward-looking statement reflects Chicago Atlantic's judgment as of the date of this conference call and carries risks and uncertainties that could make actual results diverge materially from what we currently expect. We encourage investors to look closely at the various disclosures the company has made, including the risk and other information found in the company's SEC filings. We'll also touch on certain non-GAAP measures, among them distributable earnings and adjusted distributable earnings. You can find definitions of these non-GAAP measures, along with reconciliations to the most comparable GAAP measures, in our SEC filings. I'll hand things over now to John Mazarakis. Go ahead.
John Mazarakis
executiveThank you, Tripp. Morning, everyone, and thanks for being with us today. Since this quarter marks the closing of our initial full year as a publicly traded company, I want to pause and express appreciation to the Chicago Atlantic team and to our investors, whose support turned this year into an extraordinary success. Back when we first stepped into cannabis in 2019, we viewed it as among the rare genuine pockets of alpha out there in the market. Such openings, as everyone knows, are few and far between. In our view, this sector has only just begun to reveal how much growth it can truly deliver. Last quarter I shared quite a few figures contrasting this industry's performance over the past three years against beer, wine, tobacco, and pharmaceuticals. I'd rather not revisit that territory. Still, I urge all of you to examine just how quickly cannabis has expanded relative to those sectors. Whichever data source you rely on, the industry today is valued somewhere between $30 billion and $40 billion, and it's projected to reach roughly $50 billion to $75 billion in top-line retail sales over the coming 5 years. Meeting that growth will require capital in the tens of billions of dollars, given that we're simultaneously shifting the illicit market into the legal one while new adopters keep sampling medical and adult use products. A market of this magnitude, combined with how little institutional capital has entered the space, amounts to enormous alpha; on top of that dislocation, which we've capitalized on for most of the past four years, top-tier existing debt in cannabis will soon sit within a year of maturity and will need refinancing, which means repricing. Frankly, that's the reason we chose from the very start to keep our loan maturities on the shorter end. Operators tend to be eternal optimists and keep expecting federal legalization or another piece of legislation such as SAFE to arrive shortly. Consequently, they've resisted committing to longer-term loans. That has left us negotiating from a stronger position, with greater flexibility amid an environment of rising interest rates. Our view regarding the impact of the SAFE Banking Act is likewise well settled; we don't see it as imminent. Should some version of the SAFE Banking Act ultimately become law, our belief is that we gain more than others, since we hold the largest credit platform in this space. Capital providers who aren't yet active here will want to deploy meaningful capital fast through platforms such as ours instead of developing the expertise inside their own underwriting and lending teams; beyond the SAFE Act, I should also note the state-level efforts we're monitoring. Missouri and Maryland have gone adult use, and we're actively pursuing deals in both. Minnesota is another state where we anticipate adult use cannabis being legalized before long. One thing that's really caught our attention lately is talk that AG Garland might be preparing a fresh memo on cannabis scheduling, one that would take the place of the Cole Memo that AG Sessions did away with under the Trump administration. The DOJ has been at that for a while now, but if it does get issued, the effect on us could be every bit as big as SAFE Banking. It might open the capital markets back up so more money flows to established platforms such as ours, and that would bring down our overall cost of capital, both for the REIT and for our borrowers. Right now, our strongest source of capital is our credit facility. We grew it to $92.5 million during the last quarter, and we pushed the maturity out to the end of 2024; on top of that, we kept the additional one-year extension option at no cost. As Andreas will mention later, we're hard at work broadening that banking group and increasing the size of the facility. Also, last month we seized on a request from a few institutional investors and sold $6 million of common stock at $15.16 per share. That was clearly above book. In our view it was excellent execution, and no underwriters were involved. As we said in our earnings release, we've put out an outlook for 2023. Instead of giving a specific range, we think the year is better projected through our anticipated regular quarterly dividend and our targeted payouts tied to Distributable Earnings. We anticipate a dividend of no less than $0.47 per quarter. We also anticipate continuing to pay out 90%-100% of Distributable Earnings. If we ever have to pay out a larger dividend to stay within our taxable income thresholds, we intend to handle that through a special dividend. Our feeling is that a conservative, longer-term approach will pay off better in the end. Tony, why don't you take it from here?
Tony Cappell
executiveHello, everyone. Today I want to spend my time explaining how you should view our originations, our pipeline, and what we think about the industry's overall condition. Our attention remains fixed on top-tier operators, a large number of which run vertically integrated businesses and produce at the lowest cost in the markets they serve. As we've explained previously, we track pricing in local markets on a weekly basis and keep a close watch on the direction it's moving for both cultivation and retail, while maintaining frequent communication with the people who borrow from us. What we're finding differs from one state to another. We're seeing a surge in opportunities in states that are close to approving recreational or adult use. Keep in mind that we go after states with limited licenses, favoring those that haven't yet turned recreational, and then expand alongside those operators as their demand grows. Missouri, Maryland, and Arkansas fit that profile, which is why we favor them. Now, on the subject of our current pipeline, we remain highly active throughout the whole Chicago Atlantic platform. As we mentioned during our previous call, we think we set a new pricing standard for cannabis operators by acting as lead and agent on a new facility of $350 million over four years for our biggest multi-state operator. The REIT keeps its $30 million commitment in that facility. On top of that, the REIT extended a real estate-backed loan of $11.25 million to MariMed in early January. MariMed keeps beating many of its competitors, even while exposed to markets where pricing compression is greater. Through these loans and others, we've preserved our rigorous upfront structuring, intensive monitoring of loans, and tight financial covenants. Keep in mind that we also hold all-asset liens from borrowers, which come on top of the 1.7x real estate collateral coverage across our portfolio. As we expected, we were also able to raise the share of floating rate loans from 60% one quarter ago to 83% at year-end, with appealing prime rate floors. We're fully conscious of the pressures operators face as price compression persists in numerous markets, along with higher labor costs, inflation, and a growing chance that some form of recession arrives later in the year. For lenders, evaluating such risks routinely and making sure capital is preserved is our responsibility. This young industry carries risk. Every industry does. We think our track record of direct lending in cannabis, commercial real estate, and other sectors has equipped us better to handle whatever difficulties this environment may bring. As John mentioned earlier, since many capital providers have left the sector or are currently leaving it, we can be even choosier about which operators we underwrite; this has produced conditions where demand greatly outstrips the available supply of capital, letting us tighten structures even more and raise what we're able to charge, which lifts the return on a risk-adjusted basis; we've demonstrated our ability to source appealing debt and equity capital throughout Chicago Atlantic to satisfy that demand. Our rigorous approach to underwriting gives us confidence, and together with the top-tier platform and our enduring dedication to this sector, we believe we'll remain well placed to keep delivering value for our shareholders. Andreas is going to take us through the investments we've made.
Andreas Bodmeier
executiveThank you, Tony. As of December 31, the total loan commitments in our portfolio had reached $351 million, spanning 22 portfolio companies. The weighted average yield to maturity stands at 19.7%, an increase from 18.3% on September 30. We recorded $5.9 million in net new originations for the quarter, which came from subsequent advances on delayed draw term loans to four borrowers already in the portfolio. Additionally, our new originations encompass the refinancing of two credit facilities, with outstanding principal balances of $30 million and $10.6 million, totaling $40.6 million combined. For one of those facilities, we boosted our position from $10.6 million up to $13.1 million, while keeping our $30 million hold in the other unchanged. We remain highly disciplined when it comes to deploying the REIT's available capital, concentrating on strong credit operators and meeting the growth capital needs of our existing borrowers. After year-end, we received roughly $6.5 million in early principal repayments and brought in an additional $6 million of equity capital last month. Following the expansion of the REIT's credit facility to $92.5 million, we now have $20 million in liquidity available to deploy over the coming months. Our originations pipeline is still robust, and the Chicago Atlantic platform continues to meet that demand. We continue to regard our credit facility as the main avenue for financing portfolio growth and have ongoing talks with banks about potentially joining the facility later this year. Every loan is performing. At present, approximately 83% of our portfolio is floating rate, tied to the prime rate, which marks a significant jump from just 60% floating as of Q3. That gain came about because of new loans closed during the quarter, which lets us benefit more directly from rising rates. The 140 basis point boost in our weighted average portfolio yield of 19.7% this quarter was mainly attributable to the 125 basis point rise in the prime rate. Given that the Federal Reserve is expected to keep raising the federal funds rate during the first half of this year, we anticipate yet another portfolio yield increase in Q1. Our leverage ticked up slightly, from 20% in Q3 to 22% at year-end, though we remain considerably under our initial leverage targets. I'll hand things over to Phil now so he can go over our financial results.
Phil Silverman
executiveThanks, Andreas. Now let's look at our financial results. Net interest income rose by $1.8 million, or 14.1%, reaching $14.8 million, compared to $12.9 million in Q3. For the full year, total net interest income came to $48.9 million. The Q4 gain was driven by the two prime rate increases and the Q4 refinancing of roughly $40 million in principal at better yield economics. Total operating expenses for the quarter were $5 million, versus $2.9 million in Q3. Those expenses comprised management and incentive fees of $3.3 million along with aggregate G&A and professional fees of $1.6 million. For the entire year, operating costs came to roughly $16.6 million. That figure includes $6.6 million in management and incentive fees, along with $5.7 million combined for G&A and professional fees. When you look at Q4 versus Q3, the main reason operating expenses went up is the incentive fee expense, which was $2.3 million in Q4 against $519,000 in Q3. That matches what we anticipated. As we mentioned last quarter, the incentive fee gets figured out over a rolling twelve-month period, and once we hit Q4 2022, the $1.1 million prior year incentive fee waiver tied to our IPO no longer brings down the annual incentive fee calculation. I want to point out that the bigger quarterly incentive fee we paid in Q4 2022 will have a comparable effect on the rolling twelve-month incentive fee calculation all through fiscal year 2023. Adjusted distributable earnings per share came in at $0.57 per diluted share for Q4, and $2.11 for the year ended December thirty-first, 2022. Back in January, we paid out a Q4 regular dividend of $0.47 per common share along with a special dividend of $0.29 per share, bringing total dividend distributions to shareholders to $2.10 per share for the year; that worked out to roughly 99.5% of adjusted distributable earnings. Diluted earnings per common share was $1.82 for the year ended December 31, 2022. For Q4, diluted earnings per share was $0.41, versus $0.55 in Q3. That $0.14 per common share drop was mostly because we increased the provision for expected credit losses by $2.5 million, bringing the total reserve to approximately $4 million at December 31, 2022. The quarterly CECL reserve takes into account macroeconomic conditions and borrower financial performance, plus third-party loan loss data that's representative of our portfolio. The ongoing rising rate environment and what we currently expect from portfolio company performance through the forecast period both fed into our CECL reserve, which came to approximately 1.2% of outstanding principal as of Q4. About 87% of the portfolio, based on outstanding principal, is secured by real estate, while 13% has limited or no real estate collateral. On a weighted average basis, our portfolio had real estate collateral coverage of 1.7x as of December 31, 2022. Just like in prior quarters, adjustments to Distributable Earnings meant adding back to GAAP net income the CECL reserve, stock-based compensation, and depreciation and amortization. Our book value as of December 31 was $14.86 per common share, compared with $15.23 as of September 30. The sequential decline in book value came from the $0.29 per share special dividend declared in Q4 and paid in January, plus the $0.14 fourth quarter CECL provision. Operator, we're now ready to take questions.
Aaron Hecht
analystHi everyone, I appreciate you taking my questions. So, you mentioned the various challenges weighing on the sector, like regulations, pricing on products, or access to capital. In my view, those worries have been reflected in your share price for a good while now. Could you explain to investors how you'd characterize the condition of your borrowers, your investment portfolio? Any details to provide greater reassurance or to help grasp the underwriting more thoroughly, since the portfolio's results have been quite impressive so far.
John Mazarakis
executiveRight, Aaron, I suppose there are clearly a couple of challenges in this sector — the financing piece you're referring to, plus pressure on pricing. A market where prices keep sliding is never a positive. That said, I'd say our portfolio holds up quite well. As you'll notice, and as I touched on earlier, we've made a commitment of $0.47 per share each quarter, along with a commitment to pay out 90%-100%. We'd rather keep that special dividend in reserve at the end, just to stay on the conservative side. Our thinking here is built for the long haul. We aren't showing up for just this year or this quarter. We're showing up to produce, you know, dependable returns across the coming five years. That said, we are seeing some scattered pricing compression in PA, and possibly a bit in Michigan. Once again, how we underwrite comes down to a pair of factors. When it comes to retail, our lens is dollar per square foot, and our aim is to hit above $3,000 per square foot. Should we come across a dispensary above $3,000 per square foot in California — and I repeat this constantly — we'll put money behind that dispensary, and we'll do so using the same criteria we apply when funding real estate on the retail side. On the flip side, over on cultivation, if a cultivator carries 60%-70% gross margin, the selling price essentially becomes irrelevant, and we'll put money behind that cultivator. Of course, finding such a cultivator is extremely difficult in states such as California.
Aaron Hecht
analystUh-huh.
John Mazarakis
executive...either Washington State or Oregon. You know, it just so happens that we're connected with a Michigan cultivator that has those kinds of numbers. It really varies. On the whole, the portfolio is doing quite well, and we don't anticipate any problems.
Aaron Hecht
analystUnderstood. So, I believe you set aside reserves for a few loans during this quarter. Could you give us some color on what drove that? Did certain loans shift within the CECL ratings? What's behind it, then? And second, if you consider those categories we discussed regarding risk — regulatory, product pricing, availability, capital — which of them poses the greatest challenge or the biggest risk, in your view, for your portfolio in 2023?
John Mazarakis
executiveLet me address the initial question first; our approach is simply to stay cautious. As you can observe, the companies we compete with are, well, setting aside far larger amounts than us; we have no desire to expose ourselves to needless danger. Our aim is to gradually, you know, assign a price or worth to our holdings, drawing on, you know, assessments from outside parties. We simply want to show respect for the challenges that not only the cannabis industry is displaying, but the wider economy as well. As we're aware, interest rates are going to keep climbing, and possibly somewhat more forcefully than most people expected. We're merely attempting to, you know, proceed gradually, you know, reviewing our portfolio every single day. The CECL figure you're seeing is merely a result, and the end product of several different elements, among them valuations from third parties. You know, the latter portion of your question strikes me as, harder to sort of pin down numerically. I suppose what you're asking is which concerns weigh on us the heaviest?
Aaron Hecht
analystYeah.
John Mazarakis
executiveWe'd want to see, you know, a clean shift from medical sales over to recreational, adult use in particular markets. The sooner that takes place, clearly the stronger our position. The more time it requires, the greater the worry and the exposure. Those states would be, you know, Ohio, PA, the ones that are medical, that are extremely conservative, very restricted when it comes to licenses, the count of licenses. That's likely something we'd want to see altered. For us, the SAFE Banking Act is a concern of secondary importance. Then a tertiary concern, I'd say, is how much further interest rates will climb. Should interest rates go up another 200 basis points, obviously we have, you know, a wider, somewhat bearish climate outside of cannabis that we're going to need to handle. Disposable income will collapse; that is simply going to echo across the whole economy. We're just attempting to, you know, get ready and balance all of these possible outcomes.
Aaron Hecht
analystUnderstood. Thanks for the answers, John.
John Mazarakis
executiveSure thing. Thanks, Aaron.
Gaurav Mehta
analystYeah, thanks. Good morning. I was hoping I could ask you about a few of those headwinds you mentioned, and with that in mind, how should we be thinking about the loan deployment volume you folks might see in 2023?
John Mazarakis
executiveAt this point, in terms of the coming quarter, or quarter one and Q2, we're looking at a range of $20 million to $30 million. Once again, I believe the crucial thing for us on the capital side is to keep working on building up and growing the revolver; that's truly where we expect the incremental growth to come from.
Gaurav Mehta
analystIs that $20 million to $30 million in gross originations or net?
Andreas Bodmeier
executive20 to 30. Correct.
Gaurav Mehta
analystAll right. I suppose, regarding growing the credit line, how are talks proceeding with the lenders you work with? Should we anticipate any increase during this year?
Andreas Bodmeier
executiveHi, Gaurav. Yeah. I mean, we're constantly active in the market. We talk with banks regularly, and by the close of this year, we anticipate being able to draw the entire accordion, up to $125 million.
Gaurav Mehta
analystAll right. Thanks. That's everything from me.
Mark Smith
analystHey, everyone. To start, I just wanted to discuss geographies a bit. You mentioned certain states you feel more optimistic about. Perhaps any states worth flagging that are currently causing you somewhat more stress than others where you operate today?
John Mazarakis
executiveWhen I brought up PA, that was in fact the primary state causing us concern. As for states we feel optimistic about that I didn't name, Maryland — we're extremely optimistic; in fact, we're expanding our footprint in Maryland and Missouri. Missouri has surpassed all expectations.
Mark Smith
analystAll right.
Andreas Bodmeier
executiveTo revisit what you asked about places such as Pennsylvania and Ohio — that ties directly into how we set our approach from day one. Neither has moved past medical yet. We have seen a bit of squeezing, yet the shift toward adult use has not happened so far. That serves as an offset when it comes to value overall.
Mark Smith
analystAll right. In the same vein, when you consider the pipeline, what would you say instills confidence that you can keep originating fresh loans as you examine that pipeline?
Andreas Bodmeier
executiveWell, clearly you have come across plenty of other accounts circulating out there. Looking at it through supply versus demand, the need for capital far outstrips what is available. On the subject of fresh loans, we get first choice and in the end are able to get the most out of our yields adjusted for risk, simply because competition in this space remains so thin.
Mark Smith
analystAll right. When you examine the pipeline, any split or perspective on the states where you already run operations compared with, say, additional states — whether unfamiliar to you or, alternatively, states newly arriving from a regulatory standpoint, such as Minnesota, which came up earlier? As you consider the pipeline, how does the mix break down between additional states and those where you already run operations?
John Mazarakis
executiveMark, the phrase additional states can be understood in a couple of different manners. One category covers states where activity is presently unlawful and neither medical nor adult use exists at all — those prove trickier to pinpoint. Who can say? No crystal ball sits in front of me. Regarding medical states likely to make the switch to adult use, my hunch is that Minnesota would sit near the top of any such list, since Minnesota has flipped Democratic in both its Senate and its House chambers, an odd occurrence. That had not taken place for a number of decades; it is the single state that really jumps out; regarding any others, I would merely be speculating. Naturally, Maryland already counts as rec. According to what everyone says, adult use transactions will begin on July first, though nobody has verified that as of now. Missouri just finished one entire month that beat what anyone had projected. I believe the... once that change took place, Missouri climbed to roughly 2x-3x on top-line retail revenue within a single month-over-month.
Mark Smith
analystAll right, sounds good.
John Mazarakis
executiveDuring their initial month of operation, they brought in more than $100 million in sales.
Mark Smith
analystOkay. Great. Thank you, guys.
John Mazarakis
executiveThank you.
Operator
operatorThank you. That concludes our Q&A session today. Thank you for joining.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Chicago Atlantic Real Estate Finance, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Chicago Atlantic Real Estate Finance, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chicago Atlantic Real Estate Finance, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.